CERT2 is a Ceramide based Cardiovascular Risk Score

  • Improves traditional lipid-based risk assessment and unravels hidden risk.
  • Reflects both lipid and inflammatory related risk.
  • Identifies a hidden risk in individuals not known to have coronary artery disease or elevated cholesterol levels.
  • Identifies residual risk in CVD patients.
  • Identifies residual risk in individuals believed to be on optimal lipid lowering therapy.

dScore is a ceramide-based type II diabetes risk score

  • dScore addresses ceramide mediated insulin resistance and fat versus muscle composition to give more accurate risk of type II diabetes onset.



CERT2 Predicts the risk for cardiovascular disease events:

  • Cardiovascular death
  • Non-fatal and fatal myocardial infarction
  • Stroke
  • Heart failure
  • MACE: Major adverse cardiovascular events

dScore estimates person’s probability to develop type II diabetes over the next ten years


CERT2 Indications

  • Cardiovascular patients
  • ACS patients
  • Healthy population


In clinical use

Tests are available in clinical practice as specified below and both tests worldwide for all researchers through Zora’s reference laboratory.

CERT2 is available:

  • In Finland: through Zora partners (dScore also provided)
  • United States: Mayo Medical Laboratories
  • United States: Quest Diagnostics (upcoming)
  • China: upcoming